Alcon acquires ophthalmic division

Article

Alcon will acquire the ophthalmic division of SensoMotoric Instruments (SMI).

Alcon will acquire the ophthalmic division of SensoMotoric Instruments (SMI).

SMI, a private company based in Germany, deals with ocular guidance technology such as real-time eye tracking, automatic registration of ocular imaging and IOL positing and alignment guidance.

Alcon will integrate SMI into its existing global cataract portfolio and will further develop existing products that improve patient outcomes in cataract surgery. This includes the IOL used to treat cataracts and correct refractive errors such as astigmatism and presbyopia.

Sabri Markabi, Senior Vice President of Research and Development at Alcon, commented, "This acquisition further strengthens Alcon's position in the cataract surgery market with an expansion into leading ocular tracking technology. The stare-of-the-art guidance technology provides surgeons with customization options and automated solutions, enabling optimal outcomes for their cataract patients including underlying refractive conditions."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.